Exceptional responders: In search of the science behind the miracle cancer cures

Future Oncology

Volumn 11, Issue 1, 2015, Pages 1-4

  Subbiah, Ishwaria Mohan ^a   Subbiah, Vivek ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DULANERMIN; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEW DRUG; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VORINOSTAT;

CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; DRUG APPROVAL; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; EWING SARCOMA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GERMLINE MUTATION; HODGKIN DISEASE; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; METASTASIS; NATIONAL HEALTH ORGANIZATION; NEXT GENERATION SEQUENCING; ONCOLOGIST; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGISTER; REVIEW; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PATHOLOGY;

DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PHARMACOGENETICS;

EID: 84921028558     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.204     Document Type: Review

References (17)

1. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin. Cancer Res. 19(16), 4305-4308 (2013).
2. Abrams J, Conley B, Mooney M et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2014, 71-76 (2014).
3. Mullard A. Learning from exceptional drug responders. Nat. Rev. Drug Discov. 13(6), 401-402 (2014).
4. Brannon AR, Sawyers CL. 'N of 1' case reports in the era of whole-genome sequencing. J. Clin. Invest. 123(11), 4568-4570 (2013).
5. Subbiah V, Brown RE, McGuire MF et al. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget 5(1), 95-102 (2014).
6. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104), 221 (2012).
7. Subbiah V, Westin SN, Wang K et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J. Hematol. Oncol. 7(1), 8 (2014).
8. Wagle N, Grabiner BC, Van Allen EM et al. Activating mTOR mutations in a patient with an extraordinary response on a Phase I trial of everolimus and pazopanib. Cancer Discov. 4(5), 546-553 (2014).
9. Al-Ahmadie H, Iyer G, Hohl M et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlie outlier response to cancer therapy. Cancer Discov. 4(9), 1014-1021 (2014).
10. Subbiah V, Naing A, Brown RE et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS ONE 6(4), e18424 (2011).
11. Jiang Y, Subbiah V, Janku F et al. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS ONE 9(8), e93676 (2014).
12. Jiang Y, Janku F, Subbiah V et al. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget 4(6), 884-889 (2013).
13. Subbiah V, Brown RE, Buryanek J et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol. Cancer Ther. 11(11), 2541-2546 (2012).
14. Oechsle K, Honecker F, Cheng T et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann. Oncol. 22(12), 2654-2660 (2011).
15. Feldman DR, Turkula S, Ginsberg MS et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest. New Drugs 28(4), 523-528 (2010).
16. Subbiah V, Meric-Bernstam F, Mills GB et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to sunitinib (Sutent®) a VEGFR2/PDGFRss/c-kit/FLT3/RET/CSF1R inhibitor in a Phase II trial. J. Hematol. Oncol. 7(1), 52 (2014).
17. Sheridan C. Cancer centers zero in on exceptional responders. Nat. Biotechnol. 32(8), 703-704 (2014).